Literature DB >> 27334065

Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition.

Kouichi Tamura1, Ryu Kobayashi1, Sona Haku1, Kengo Azushima1, Hiromichi Wakui1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27334065     DOI： 10.1038/hr.2016.71

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  17 in total

1.  Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Authors:  Luis Miguel Ruilope; Andrej Dukat; Michael Böhm; Yves Lacourcière; Jianjian Gong; Martin P Lefkowitz
Journal:  Lancet       Date:  2010-03-16       Impact factor: 79.321

2.  An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention.

Authors:  Alan S Go; Mary Ann Bauman; Sallyann M Coleman King; Gregg C Fonarow; Willie Lawrence; Kim A Williams; Eduardo Sanchez
Journal:  Hypertension       Date:  2013-11-15       Impact factor: 10.190

3.  Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.

Authors:  Giuseppe Mulè; Emilio Nardi; Laura Guarino; Valentina Cacciatore; Giulio Geraci; Ilenia Calcaterra; Bruno Oddo; Francesco Vaccaro; Santina Cottone
Journal:  Hypertens Res       Date:  2015-01-08       Impact factor: 3.872

4.  Aldosterone and abnormal left ventricular geometry in chronic kidney disease.

Authors:  Cesare Cuspidi; Marijana Tadic; Carla Sala
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

5.  Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Kazuomi Kario; Ningling Sun; Fu-Tien Chiang; Ouppatham Supasyndh; Sang Hong Baek; Akiko Inubushi-Molessa; Ying Zhang; Hiromi Gotou; Martin Lefkowitz; Jack Zhang
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

6.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014).

Authors:  Kazuaki Shimamoto; Katsuyuki Ando; Toshiro Fujita; Naoyuki Hasebe; Jitsuo Higaki; Masatsugu Horiuchi; Yutaka Imai; Tsutomu Imaizumi; Toshihiko Ishimitsu; Masaaki Ito; Sadayoshi Ito; Hiroshi Itoh; Hiroshi Iwao; Hisashi Kai; Kazuomi Kario; Naoki Kashihara; Yuhei Kawano; Shokei Kim-Mitsuyama; Genjiro Kimura; Katsuhiko Kohara; Issei Komuro; Hiroo Kumagai; Hideo Matsuura; Katsuyuki Miura; Ryuichi Morishita; Mitsuhide Naruse; Koichi Node; Yusuke Ohya; Hiromi Rakugi; Ikuo Saito; Shigeyuki Saitoh; Kazuyuki Shimada; Tatsuo Shimosawa; Hiromichi Suzuki; Kouichi Tamura; Norio Tanahashi; Takuya Tsuchihashi; Makoto Uchiyama; Shinichiro Ueda; Satoshi Umemura
Journal:  Hypertens Res       Date:  2014-04       Impact factor: 3.872

Review 7.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Authors:  Scott A Hubers; Nancy J Brown
Journal:  Circulation       Date:  2016-03-15       Impact factor: 29.690

8.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

Review 9.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

10.  Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

Authors:  Sadayoshi Ito; Minoru Satoh; Yuko Tamaki; Hiromi Gotou; Alan Charney; Naoko Okino; Mizuki Akahori; Jack Zhang
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.